Annual report [Section 13 and 15(d), not S-K Item 405]

Fair Value of Financial Instruments - Narrative (Details)

v3.25.0.1
Fair Value of Financial Instruments - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Apr. 14, 2022
Dec. 31, 2024
Dec. 31, 2023
Sep. 30, 2021
Subsidiary, Sale of Stock [Line Items]        
Increase (decrease) in fair value of private warrant liability   $ 51,960 $ 2,011  
Fair value, asset, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income   Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)  
Fair value, liability, recurring basis, unobservable input reconciliation, gain (loss), statement of income or comprehensive income   Other Nonoperating Income (Expense) Other Nonoperating Income (Expense)  
Private Warrants        
Subsidiary, Sale of Stock [Line Items]        
Warrants outstanding (in shares)   7,732,168 7,732,168 7,732,168
Number of warrants to purchase common stock (in shares)       1
Fair value (in dollars per share)   $ 7.15 $ 0.43  
Increase (decrease) in fair value of private warrant liability   $ 51,960 $ 2,011  
Public Warrants        
Subsidiary, Sale of Stock [Line Items]        
Warrants outstanding (in shares)   8,188,811 8,188,811  
Number of warrants to purchase common stock (in shares)   1    
Fair value (in dollars per share)       $ 11.50
Committed equity facility        
Subsidiary, Sale of Stock [Line Items]        
Share purchase period 24 months      
Beneficial ownership percentage 4.99%      
Sale of stock, amount authorized to issue and sell $ 80,000      
Percentage of purchase price per share 0.97      
Percentage of commission on gross proceeds 3.00%      
Shares from transaction (in shares)   0 497,392  
Aggregate gross proceeds     $ 1,200  
Changes in fair value   $ 0 $ (216)